Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 353

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Assessment of Disparities in Digital Access Among Medicare Beneficiaries and Implications for Telemedicine

Open access
Roberts, Eric T., Mehrotra, Ateev·2020·JAMA Internal Medicine

Abstract

quine from retail pharmacies, including an approximate additional 93 000 patients who received both hydroxychloroquine and azithromycin.First, evidence of efficacy in preventing or treating COVID-19 is limited.Treatment guidelines found insufficient clinical data to recommend for or against hydroxychloroquine or chloroquine use and recommend against combining either with azithromycin, except in clinical trials. 1 Second, because of reports of cardiac and other adverse events, the US Food and Drug Administration has cautioned against using hydroxychloroquine or chloroquine for COVID-19 outside of hospitalized settings or clinical trials.5 If azithromycin is used with hydroxychloroquine or chloroquine, correcting electrolyte levels, completing electrocardiographic monitoring, and avoiding other QTc interval-prolonging drugs are recommended.6 Third, sudden increases in demand for hydroxychloroquine and chloroquine limit availability for FDAapproved uses for rheumatoid arthritis, lupus, and malaria.5 While some of the largest increases in hydroxychloroquine and chloroquine dispensing occurred in states with high COVID-19 case rates (eg, New Jersey, New York), other states with large increases in dispensing had moderate (eg, Florida) or low (eg, Hawaii) case rates.These data do not include prescribing indication, so not all increased dispensing may be for COVID-19.It is unknown if patients immediately used or saved these medications.Finally, data were collected prior to release of many treatment guidelines and as state board of pharmacy dispensing regulations for hydroxychloroquine and chloroquine were evolving.2 As COVID-19 continues to spread, ongoing assessment of the use of potential therapies will be essential to inform safe and appropriate treatment, along with prompt adverse event reporting to FDA's MedWatch safety reporting program (https:// www.fda.gov/safety/medwatch-fda-safety-information-and- adverse-event-reporting-program).State-specific data can help target efforts to improve prescribing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamainternmed.2020.2666

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 353

Metadata

Authors
Roberts, E. T., & Mehrotra, A.
Venue
JAMA Internal Medicine
Published
2020-10-01
Volume
180
Issue
10
Pages
1386
ISSN
2168-6106 (ISSN-L)
OpenAlex
W3046994664
Cited by
353
References
3
FWCI
40.61
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessment of Disparities in Digital Access Among Medicare Beneficiaries and Implications for Telemedicine. https://app.cochat.ai/papers/10.1001/jamainternmed.2020.2666
The paper
Roberts, E. T., & Mehrotra, A. (2020). Assessment of Disparities in Digital Access Among Medicare Beneficiaries and Implications for Telemedicine. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2020.2666

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.